AbbVie has entered new collaborations to advance early-stage research in key therapeutic areas such as oncology and immunology. AbbVie and Pure MHC entered a research and license agreement to discover and validate peptide targets for use with T-cell receptor therapeutics in several types of cancers.Pure MHC has developed technology to identify novel, tumor-associated peptides based on innovation licensed from the University of Oklahoma. The collaboration aims to identify a library of peptide ...